Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nano-X rotation study for cancer patients ends early

NCT ID NCT02995603

Knowledge-focused Sponsor: University of Sydney Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how cancer patients experience being rotated horizontally in the Nano-X system. 43 patients completed questionnaires about anxiety and motion sickness before and after rotation. The study was terminated early, so findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What could go wrong
The study was terminated early, so results are limited and may not be reliable. It only measured patient experience, not treatment effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

43 people

The number who actually took part.

Started

Dec 2019

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. A diagnosis of cancer, any stage 2. ≥18 years of age 3. Eastern Cooperative Oncology Group (ECOG) status 0-2 4. Currently or previously being treated with radiotherapy 5. Any prior therapy allowed 6. Willing and able to comply with all study requirements 7. Must be able to read and complete questionnaires in English 8. Signed, written informed consent Exclusion Criteria: 1. Pregnant women 2. Mentally impaired patients or patients for whom attaining informed consent would be difficult (including language barriers) 3. Severe vertigo or recent diagnosis of Benign Paroxysmal Positioning Vertigo

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • Prince of Wales Hospital

    Randwick, New South Wales, 2031, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.